血栓药物市场- 按药物类别（抗凝血剂[维生素K、DOA、肝素、Xa 抑制剂]、抗血小板药物[P2Y12、阿斯匹灵、糖蛋白]、血栓溶解剂）、疾病类型（DVT、PE、VTE、 AT）、RoA、配销通路- 全球预测，2024 - 2032

由于深部静脉血栓 (DVT) 和肺栓塞 (PE) 等血栓性疾病的盛行率不断增加，预计血栓药物市场规模在 2024 年至 2032 年间将呈现 8.2% 的复合年增长率。人口老化、久坐的生活方式以及肥胖和糖尿病等与生活方式相关的疾病发生率上升，都刺激了对血栓药物的需求。

药物传输技术、新型疗法和口服抗凝血剂的引入的重大发展正在为增强治疗选择和改善患者预后铺平道路。例如，2023年11月，美国FDA批准了Adzynma，这是第一个重组基因工程蛋白产品，设计用于诊断患有先天性血栓性血小板减少性紫斑症的成人和儿童患者进行预防性或按需酶替代治疗。

此外，政府为提高对血栓形成的认识和改善医疗服务的可及性而采取的倡议正在积极影响市场的成长轨迹。

血栓药物产业分为药物类别、疾病类型、给药途径、配销通路和地区。

就药品类别而言，由于心血管疾病发生率上升，预计2024年至2032年抗血小板药物领域的产业规模复合年增长率将达到8.5%。这些疾病需要抗血小板治疗来预防心臟病和中风等血栓事件。药物配方的不断进步正在导致新型抗血小板药物的开发，其功效和安全性得到改善。人们对预防保健和抗血栓治疗重要性的认识不断增强，将推动产品需求。

就疾病类型而言，到2032 年，深部静脉栓塞(DVT) 领域的血栓药物市场复合年增长率可能达到8.7%。率不断增加。人口老化、久坐的生活方式和不断上升的肥胖率正在推动 DVT 的流行，从而刺激了针对这种特定疾病类型的血栓形成药物的需求。

从地区来看，由于心血管疾病以及肥胖和高血压等相关危险因子的盛行率不断上升，预计欧洲血栓药物产业在 2024 年至 2032 年间将成长 7.6%。医疗保健支出的增加、药物研究的进步以及强大的医疗保健基础设施的存在正在增加这些药物的消费。多项政府措施正在进一步促进预防性医疗保健措施并改善该地区获得血栓治疗的机会。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 血栓性疾病盛行率增加
    • 外科手术数量不断增加
    • 药物开发和技术的进步
    • 越来越重视预防保健
  • 产业陷阱与挑战
    • 与血栓药物相关的高成本
    • 不良反应和副作用的风险
• 成长潜力分析
• 波特的分析
• PESTEL分析
• 监管环境
• 技术景观
• 报销场景
• 2023 年定价分析
• 未来市场趋势
• 缺口分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 抗凝血剂
  • 直接口服抗凝血药
  • 肝素
  • 维生素K拮抗剂
  • Xa抑制剂
• 抗血小板药物
  • P2Y12血小板抑制剂
  • 阿斯匹林
  • 糖蛋白 IIb/IIIa 抑制剂
• 溶栓药物

第 6 章：市场估计与预测：按疾病类型，2021 - 2032 年

• 主要趋势
• 静脉血栓栓塞
• 深层静脉栓塞
• 肺栓塞
• 动脉血栓形成
• 其他疾病类型

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 口服
• 注射用
• 专题

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Amgen Inc.
• Aspen Pharmacare Holdings Limited
• Baxter International Inc.
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• GlaxoSmithKline plc
• Janssen Pharmaceuticals, Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi

Thrombosis Drugs Market size is projected to showcase 8.2% CAGR between 2024 and 2032, led by the increasing prevalence of thrombotic disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). The aging population, sedentary lifestyles, and rising incidence of lifestyle-related diseases like obesity and diabetes are fueling the demand for thrombosis drugs.

Significant developments in drug delivery technologies, novel therapeutics, and the introduction of oral anticoagulants are making way for enhanced treatment options and patient outcomes. For instance, in November 2023, the U.S. FDA authorized Adzynma, the first recombinant genetically engineered protein product designed for preventive or on-demand enzyme replacement therapy in adult and pediatric patients diagnosed with congenital thrombotic thrombocytopenic purpura.

Furthermore, government initiatives to raise awareness about thrombosis and improve access to healthcare services are positively influencing the market growth trajectory.

The thrombosis drugs industry is bifurcated into drug class, disease type, route of administration, distribution channel, and region.

In terms of drug class, the industry size from the antiplatelet drugs segment is expected to record 8.5% CAGR from 2024 to 2032, owing to the rising incidence of cardiovascular diseases. These ailments are necessitating antiplatelet therapies to prevent thrombotic events like heart attacks and strokes. Rising advancements in drug formulations is leading to the development of novel antiplatelet agents with improved efficacy and safety profiles. The growing awareness about preventive healthcare and the importance of antithrombotic therapy will drive the product demand.

With respect to disease type, the thrombosis drugs market from the deep vein thrombosis (DVT) segment may witness 8.7% CAGR through 2032. This can be attributed to the increasing incidence of DVT due to factors like prolonged immobility, surgery, and certain medical conditions. The aging population, sedentary lifestyles, and rising obesity rates are driving the prevalence of DVT, thereby fueling the demand for thrombosis drugs targeting this specific disease type.

Regionally, the Europe thrombosis drugs industry is projected to depict 7.6% gains between 2024 and 2032, due to growing prevalence of cardiovascular diseases and related risk factors like obesity and hypertension. The increasing healthcare expenditure, advancements in pharmaceutical research, and the presence of robust healthcare infrastructure are increasing the consumption of these drugs. Several government initiatives are further promoting preventive healthcare measures and improving access to thrombosis treatments in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of thrombotic disorders
    • 3.2.1.2 Rising number of surgical procedures
    • 3.2.1.3 Advancements in drug development and technology
    • 3.2.1.4 Growing emphasis on preventive healthcare
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with thrombosis drugs
    • 3.2.2.2 Risk of adverse reactions and side effects
• 3.3 Growth potential analysis
• 3.4 Porter's analysis
• 3.5 PESTEL analysis
• 3.6 Regulatory landscape
• 3.7 Technological landscape
• 3.8 Reimbursement scenario
• 3.9 Pricing analysis, 2023
• 3.10 Future market trends
• 3.11 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Anticoagulants
  • 5.2.1 Direct oral anticoagulants
  • 5.2.2 Heparin
  • 5.2.3 Vitamin K antagonists
  • 5.2.4 Xa Inhibitor
• 5.3 Antiplatelet drugs
  • 5.3.1 P2Y12 platelet inhibitor
  • 5.3.2 Aspirin
  • 5.3.3 Glycoprotein IIb/IIIa inhibitors
• 5.4 Thrombolytic drugs

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Venous thromboembolism
• 6.3 Deep vein thrombosis
• 6.4 Pulmonary embolism
• 6.5 Arterial thrombosis
• 6.6 Other disease types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Topical

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Amgen Inc.
• 10.2 Aspen Pharmacare Holdings Limited
• 10.3 Baxter International Inc.
• 10.4 Bayer AG
• 10.5 Boehringer Ingelheim GmbH
• 10.6 Bristol-Myers Squibb Company
• 10.7 Daiichi Sankyo Company, Limited
• 10.8 GlaxoSmithKline plc
• 10.9 Janssen Pharmaceuticals, Inc.
• 10.10 Novartis AG
• 10.11 Pfizer Inc.
• 10.12 Sanofi